세계 에리스로포이에틴 제제 시장 규모는 2023년 110억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장이 2024-2032년 사이 5%의 연평균 성장률(CAGR)을 기록하며 173억 달러에 달할 것으로 예측했습니다. 빈혈과 암의 유병률 증가, 만성 신장 질환 치료에 대한 적용 증가, 약물의 잠재적 효과에 대한 대중의 인식 증가가 시장을 이끄는 주요 요인 중 일부입니다.
에리스로포이에틴(EPO) 제제는 에포에틴 알파, 에포에틴 베타, 달베포에틴 알파 등 다양한 약물로 구성되어 있으며, 체내 EPO 결핍을 치료하기 위해 소비됩니다. 이들은 재조합 데옥시리보핵산(DNA) 기술을 이용하여 합성적으로 제조됩니다. 골수에서 적혈구(RBC) 생성을 자극하여 체내 헤모글로빈 농도를 조절합니다. 체내 적혈구의 양을 건강하게 유지하면서 지구력 강화, 피로감 감소, 신진대사 개선, 근육 치유 과정 개선에 도움을 줍니다. 빈혈, 말기 신부전, 인체면역결핍바이러스(HIV), 혈액학 등 다양한 질병을 치료하는 데 사용됩니다. 이 외에도 EPO 제제는 근육에 산소 공급 능력을 향상시키는 효과가 있기 때문에 운동 선수의 운동 능력과 유산소 운동 능력을 향상시키기 위해 소비됩니다.
현재 암과 신경질환(자폐증, 뇌종양, 뇌성마비, 간질, 주의력결핍장애(ADD) 등)의 유병률 증가로 인해 EPO 제제에 대한 대중의 수요가 증가하고 있는 것은 시장 성장을 뒷받침하는 중요한 요인 중 하나입니다. 여기에 EPO 약물과 그 효과에 대한 대중의 인식이 높아지면서 시장 전망을 밝게 하고 있습니다. 또한, 전 세계 대중들 사이에서 외과적 개입에 대한 필요성이 증가하고 있습니다. 이는 환자의 수술 후 동종 수혈을 줄이기 위해 EPO 약물의 사용이 증가함에 따라 시장 성장을 촉진하고 있습니다. 이와는 별도로 전 세계 개인의 만성 신장 질환(CKD) 환자 수가 증가함에 따라 업계 투자자에게 유리한 성장 기회를 제공하고 있습니다. 또한, 적혈구(RBC) 증가 및 피로 감소와 같은 EPO 약물이 제공하는 다양한 이점이 시장에 긍정적인 영향을 미치고 있습니다. 이와 더불어, 전 세계적으로 에리스로포이에틴 바이오시밀러가 빠르게 상용화되고 있는 것도 시장 성장을 촉진하고 있습니다. 이는 전 세계적으로 레퍼런스 의약품보다 바이오시밀러 의약품에 대한 선호도가 높아지는 추세와 함께 시장 성장에 기여하고 있습니다. 또한, 새로운 치료제로서 EPO 제제가 연구 기관에서 많은 연구 목적으로 활용되고 있는 것도 시장 성장을 촉진하고 있습니다.
The global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.
Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.
At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market. Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, product type, application and end user.
Biologics
Biosimilars
The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.
Hematology
Kidney Disorder
Cancer
Others
A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.
Hospitals
Homecare
Specialty Clinics
Others
A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.